Ganymed is developing monoclonal antibody therapeutics against solid tumors, where current therapies are poor and where there is an overriding medical need. Ganymed’s pan cancer surface antigens are uniquely specific for cancer tissues and can be expected to show greater therapeutic efficacy and better safety allowing significant reduction in time to market.

Ganymed was sold to ATS in 2008.

Menu